Comprehensive US government program for dried plasma development

Transfusion

Volumn 56, Issue , 2016, Pages S16-S23

  Pusateri, Anthony E ^a   Given, Michael B ^b   MacDonald, Victor W ^c   Homer, Mary J ^d  

^a U S ARMY MEDICAL RESEARCH AND MATERIEL COMMAND   (United States)

^b OFFICE OF NAVAL RESEARCH   (United States)

^c US Army Medical Materiel Development Activity   (United States)

^d U S DEPARTMENT OF HEALTH AND HUMAN SERVICES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMA SUBSTITUTE;

ARTICLE; BATTLE INJURY; BLEEDING; BLOOD DONOR; BLOOD SAFETY; BLOOD TRANSFUSION; COST CONTROL; DRIED PLASMA; EMERGENCY CARE; FOOD AND DRUG ADMINISTRATION; FREEZE DRYING; HEMORRHAGIC SHOCK; HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PLASMA; PLASMA TRANSFUSION; PROCESS OPTIMIZATION; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SPRAY DRYING; SURGE CAPACITY; UNITED STATES; MILITARY MEDICINE; PROCEDURES; PUBLIC HEALTH;

HUMANS; MILITARY MEDICINE; NATIONAL HEALTH PROGRAMS; PLASMA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84961786470     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.13331     Document Type: Article

References (29)

1. Borgman MA, Spinella PC, Perkins JG, et al., The ratio of blood products transfused affects mortality in patients receiving massive transfusions at a combat support hospital. J Trauma. 2007; 63: 805-13.
2. Spinella PC, Dunne J, Beilman GJ, et al., Constant challenges and evolution of US military transfusion medicine and blood operations in combat. Transfusion 2012; 52: 1146-53.
3. Maegele M, Lefering R, Yucel N, et al., Early coagulopathy in multiple injury: an analysis from the German Trauma Registry on 8724 patients. Injury 2007; 38: 298-304.
4. Zink KA, Sambasivan CN, Holcomb JB, et al., A high ratio of plasma and platelets to packed red blood cells in the first 6 hours of massive transfusion improves outcomes in a large multicenter study. Am J Surg 2009; 197: 565-70.
5. Holcomb JB, del Junco DJ, Fox EF, et al., The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. JAMA Surg 2013; 148: 127-36.
6. Brown JB, Cohen MJ, Minei JP, et al., Debunking the survival bias myth: characterization of mortality during the initial 24 hours for patients requiring massive transfusion. J Trauma Acute Care Surg 2012; 73: 358-64.
7. Eastridge BJ, Mabry RL, Seguin P, et al., Death on the battlefield (2001-2011): implications for the future of combat casualty care. J Trauma Acute Care Surg 2012; 73: S431-7.
8. Malsby RF III, Quesada J, Powell-Dunford N, et al., Prehospital blood product transfusion by U.S. army MEDEVAC during combat operations in Afghanistan: a process improvement initiative. Mil Med 2013; 178: 785-91.
9. Schmidt PJ., The plasma wars: a history. Transfusion 2012; 52: 2S-4S.
10. Harding AJ., A brief history of blood transfusion. Biomed Scientist 2005; 49: 1147-57.
11. Rappaport EM., Hepatitis following blood or plasma transfusions. JAMA 1945; 128: 932-9.
12. Kendrick DB., Blood program in World War II. Washington (DC): Office of the Surgeon General, Department of the Army; 1964.
13. Statement on normal (whole pooled) human plasma prepared by Committee on Plasma and Plasma Substitutes of the Division of Medical Sciences, National Research Council. Transfusion 1968; 8: 57-9.
14. Sailliol A, Martinaud C, Cap AP, et al., The evolving role of lyophilized plasma in remote damage control resuscitation in the French Armed Forces Health Service. Transfusion 2013; 53Suppl1: 65S-71S.
15. Bux J, Dickhorner D, Scheel E., Quality of freeze-dried (lyophilized) quarantined single-donor plasma. Transfusion 2013; 53: 3203-9.
16. Solheim BG, Chetty R, Flesland O., Indications for use and cost-effectiveness of pathogen-reduced ABO-universal plasma. Curr Opin Hematol 2008; 15: 612-7.
17. Bioplasma FDP product information [Internet]. Pinetown (South Africa): National Bioproducts Institute; c2015 [cited 2015 Jul 16]. Available at: http://www.nbi-sa.co.za/index.php/products/30-products/90-pharmaceuticals
18. Rock G., A comparison of methods of pathogen inactivation of FFP. Vox Sang 2011; 100: 169-78.
19. Booth GS, Lozier JN, Nghiem K, et al., SPRAY: single donor plasma product for room temperature storage. Transfusion 2012; 52: 828-33.
20. Hellstern P, Solheim BG., The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 2011; 38: 65-70.
21. Cancelas J, Rugg N, Pratt PG, et al., A safety clinical trial of dose-escalation of autologous lyophilized plasma versus fresh frozen plasma in normal healthy subjects. Transfusion 2011; 51(Suppl): S85-040A.
22. Winata E, Culbertson KE, Egan A, et al., Production of single donor lyophilized plasma for phase I clinical trials. Transfusion 2011; 51 (Suppl): SP21.
23. Stramer SL., Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2014; 9: 30-36.
24. Brummel-Ziedins K, Vossen CY, Rosendaal FR, et al., The plasma hemostatic proteome: thrombin generation in healthy individuals. J Thromb Haemost 2005; 3: 1472-81.
25. ®) versus fresh frozen plasma (FFP) in critically ill patients in the UK. Transfus Apher Sci 2010; 43: 251-259.
26. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, et al., Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 2006; 16: 266-75.
27. Moore EE, Chin TL, Chapman MC, et al., Plasma first in the field for postinjury hemorrhagic shock. Shock 2014; 41: 35-38.
28. Brown JB, Guyette FX, Neal MD, et al., Taking the blood bank to the field: the design and rationale of the Prehospital Air Medical Plasma (PAMPer) trial. Prehosp Emerg Care 2015; 19: 343-50.
29. Levi M, Toh CH, Thachil J, Watson HG., Guidelines for the diagnosis and management of disseminated intravascular coagulation. Br J Haematol 2009; 145: 24-33.